Epigenetic alterations like DNA methylation and the resulting inactivation of cancer-related genes often contribute to the development of various cancers. To identify the genes that are silenced by aberrant methylation in renal cell carcinoma (RCC), we subjected two RCC lines to methylated CpG island amplification/representational difference analysis. This identified 27 CpG islands. Combined bisulfite restriction analysis of these CpG islands in primary RCC cases revealed that four were methylated in a tumor-specific manner. One of these was identified as the human homeo-box gene B13 (HOXB13) gene, but the remaining three CpG islands were not associated with known genes. The methylation frequencies of HOXB13 in primary RCC samples and lines were 30 and 73%, respectively. The methylation status of HOXB13 correlated with the loss of its expression both in RCC lines and primary tumors, and methyltransferase inhibitor treatment induced the recovery of its expression. Exogenous expression of HOXB13 in RCC cells that lacked endogenous HOXB13 expression suppressed colony formation and induced apoptotic features. Furthermore, HOXB13 methylation correlated positively with tumor grade and microvessel invasion. These results suggest that HOXB13 is a novel candidate tumor suppressor gene in RCC and that its inactivation may play an important role in both RCC tumorigenesis and progression.
Introduction
The functional loss of tumor suppressor genes is a fundamental cause of cancer progression. These genes may be silenced not only by genetic alterations such as mutation or allelic deletion but also by epigenetic changes. Indeed, aberrant DNA methylation in the promoter region has been implicated in the transcriptional silencing of several tumor suppressor genes in various cancers (Jones and Laird, 1999; Toyota and Issa, 1999; Baylin et al., 2001; Herman and Baylin, 2003) .
Renal cell carcinoma (RCC) is the most common cancer of the human kidney (Thoenes et al., 1986) . There are more than 30 000 newly diagnosed cases in the USA and 7000 occur in Japan every year. Previous studies revealed that the von Hippel-Lindau (VHL) gene is the major tumor suppressor gene that participates in the development of human RCC, as it is inactivated, mostly by genetic alterations, in about 60% of sporadic RCC cases (Foster et al., 1994; Gnarra et al., 1994; Herman et al., 1994; Shuin et al., 1994 Shuin et al., , 1999 . However, the tumorigenic mechanisms for the sporadic RCCs that lack VHL gene inactivation and the multi-step processes involved in RCC progression remain unclear. Recently, the fumarate hydratase (FH) and Bert Hogg Dube (BHD) genes were identified by positional cloning as candidate tumor suppressor genes in RCC, but they appear to mainly participate in the development of hereditary human RCC (Nickerson et al., 2002; Tomlinson et al., 2002) . To identify the genes inactivated in sporadic RCC, several studies attempted to clarify the methylation status of some cancer-related genes in RCC that are known to be epigenetically inactivated in other human cancers. However, since it had been estimated that up to several hundred genes are aberrantly methylated in cancer (Costello et al., 2000) , there might be some other unidentified genes that are specifically inactivated in RCC by aberrant promoter methylation and play a more fundamental role in RCC development.
To date, comprehensive genomic screening of human RCC to identify aberrantly methylated genes has not been performed. To identify novel epigenetically inactivated genes in RCC, we used methylated CpG island amplification/representational difference analysis (MCA/RDA). This allowed us to identify differentially methylated CpG islands in RCC line. Subsequent analysis of the methylation of these CpG islands in primary tumor samples and paired normal tissues revealed that the human homeo-box gene B13 (HOXB13) was specifically methylated at a much higher rate in the primary renal tumors, and showed a higher methylation frequency than the other CpG islands we detected.
Homeo-box (Hox) genes encode transcription factors and play important roles in the development of vertebrates. Murine Hoxb13 is expressed in the urogenital system, the tailbud, the posterior extremity of the spinal cord, and the hindgut of embryonic mice (Zeltser et al., 1996) . Since homozygous Hoxb13 mutant mice showed an overgrown tail phenotype with increased cell proliferation and decreased apoptosis in the tail, the function of Hoxb13 was predicted to repress cell growth and activate programmed cell death in the mouse . However, the function of HOXB13 in human adult kidney and its involvement in renal tumorigenesis is unclear.
Our results showed that HOXB13 was aberrantly methylated in both primary RCC tumors and lines with high frequencies. The loss of HOXB13 expression in primary RCC tumors and lines correlated with its methylation, and its expression recovered when HOXB13-negative lines were treated with a methyltransferase inhibitor. This shows HOXB13 expression is controlled in a methylation-dependent manner. Moreover, exogenous expression of HOXB13 in hypermethylated RCC cells that did not express this gene suppressed cell proliferation and induced apoptotic features. These findings suggest that HOXB13 acts as a tumor suppressor gene in human RCC.
Results
Identification of differentially methylated CpG islands in RCC by MCA/RDA The MCA/RDA technique (Toyota et al., 1999b) was used to identify CpG islands that are differentially methylated in RCC. In this analysis, the MCA amplicon from either the KMRC-1 or KMRC-2 RCC cell line was used as the tester, while the MCA amplicon from a mixture of DNA derived from the normal kidney tissue of four individuals served as the driver. The DNA sequences of 195 randomly selected clones were determined and homology searching using the BLAST program revealed that 27 of these clones (denoted as MIRC [Methylated in Renal Cancer] clones) were independent of each other and had homology to GenBank sequences, some of which were known gene sequences. All of these fragments contain CpG islands that satisfied the criteria of CpG islands (i.e. length >200 bp, GC content >50%, ObsCpG/ExpCpG>0.6) (Gardiner-Garden and Frommer, 1987) .
Methylation status of HOXB13 in primary RCC samples and lines Since the MCA/RDA had been used with established RCC cell lines, we further confirmed the tumor-specific methylation of these isolated CpG islands in primary RCCs by combined bisulfite restriction analysis (COBRA) using paired normal kidney tissues obtained at the time of surgical resection for comparison. Only four clones (Table 1, MIRC8, 9, 11, and 17) showed strict tumor-specific methylation and higher methylation frequencies. BLAST searching identified MIRC9 as the 5 0 flanking region of the HOXB13 gene, which is on chromosome 17q21.2 (GenBank accession no. U57052). Thus, DNA methylation of the 5 0 region of the HOXB13 gene, as shown in Figure 1a , may lead to its gene silencing and thereby participate in the development of RCC. However, which genes are related to the other three CpG islands (MIRC8, 11, and 17) remains unclear. The differential methylation of HOXB13 in primary RCCs was examined by COBRA among 56 primary RCCs and their adjacent normal tissue samples. Aberrant tumor-specific methylation of HOXB13 was detected in 17 of the 56 (30%) primary RCCs (Figure 1b) . No methylation was detected in the adjacent normal kidney tissue samples.
To evaluate the extent to which the CpG islands in the HOXB13 upstream region were methylated, we subjected three primary RCCs that showed HOXB13 methylation along with their adjacent normal tissue samples to bisulfite sequencing (Figure 1c ). The tumorspecific differential methylation of the CpG sites shown by COBRA employing the BstUI restriction enzyme was confirmed by the bisulfite sequencing. Moreover, other CpG islands also showed a tendency towards increased methylation in the tumor-derived samples.
To further investigate HOXB13 methylation in RCC, we subjected 15 RCC lines to COBRA. Aberrant methylation of HOXB13 was detected in 11 of them (73%) (Figure 2a ). The HOXB13 upstream region was almost completely methylated in four of the lines, The presence of CpG islands was determined on the basis of the following criteria: length >200 bp, %GC>50%, ObsCpG/ExpCpG>0.60.
HOXB13 methylation in renal cell carcinoma H Okuda et al namely UMRC-6, KC-12, VHL-renal, and SKRC-7, while partial methylation was observed in seven other lines (786-O, A498, Caki-1, Caki-2, SKRC-1, TUHR4TKB, and TUHR14TKB) (Figure 2a ). To confirm the methylation status of each CpG site in the RCC lines, two hypermethylated lines (UMRC-6 and SKRC-7), one partially methylated line (TUHR4TKB), and one unmethylated line (ACHN) were subjected to bisulfite sequencing (Figure 2b ). In both highly methylated lines, all the CpG sites analysed were densely methylated. In contrast, the unmethylated line showed almost no methylation in the entire region, while the partially methylated line showed moderate methylation.
HOXB13 methylation is associated with gene silencing Although abundant expression of HOXB13 in normal prostate and colorectal tissues of adult mouse and humans has been reported (Sreenath et al., 1999; Jung et al., 2004b) , our reverse transcription-PCR (RT-PCR) analysis revealed that HOXB13 is also expressed in the normal human kidney, testis, uterus, placenta, and thymus in addition to the prostate (Figure 3a ). To elucidate whether aberrant methylation of HOXB13 is associated with the loss of its expression in RCCs, we analysed the expression of HOXB13 in 15 RCC lines by RT-PCR that amplified the HOXB13 cDNA to plateau levels ( Figure 3b ). The four hypermethylated lines HOXB13 methylation in renal cell carcinoma H Okuda et al (UMRC-6, KC-12, VHL-renal, and SKRC-7) showed complete loss of HOXB13 expression. This indicates that methylation of the 5 0 region of HOXB13 correlates with its loss of expression.
To further estimate the effect of methylation on HOXB13 silencing, three hypermethylated RCC lines (UMRC-6, KC-12 and VHL-renal) were cultured for 3 days in medium containing 1 mM of the methylation inhibitor 5-aza-2 0 -deoxycytidine (5-aza-dC). Alternatively, since it is known that the deacetylation of histone is also involved in gene silencing caused by DNA methylation, the cells were treated with 300 nM of the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) for 24 h. As shown in Figure 3c , all cell lines reexpressed HOXB13 when they were treated with 5-azadC. However, TSA alone did not induce the recovery of HOXB13 expression. Although a synergistic effect of TSA with 5-aza-dC in enhancing HOXB13 expression was seen with the VHL-renal line, the effect was not observed in the UMRC-6 and KC-12 lines. These results suggest that the silencing of HOXB13 is mainly controlled in a methylation-dependent manner.
Correlation between methylation status and expression of HOXB13 in primary RCC To evaluate whether aberrant methylation of HOXB13 causes loss of its expression in primary RCC samples as well, immunohistochemical analysis using a polyclonal rabbit anti-HOXB13 antibody was performed ( Figure 4 ). In total, we examined 11 RCCs with clear cell histology (Figure 4a ), three of which showed HOXB13 methylation, while the remaining eight lacked HOXB13 methylation. In the latter eight RCCs, positive immunostaining with the anti-HOXB13 antibody in the cytoplasm was observed (Figure 4b ). In contrast, no cytoplasmic immunoreaction with the anti-HOXB13 antibody was detected in the three primary RCCs that showed HOXB13 methylation (Figure 4c 
Expression of HOXB13 in a hypermethylated RCC line inhibits colony formation
The high frequency of tumor-specific HOXB13 methylation and its associated gene silencing in RCC suggests that HOXB13 inactivation may be involved in the tumorigenesis or malignant progression of renal cancer. To clarify whether HOXB13 acts as a tumor suppressor, RT-PCR analysis of HOXB13 expression in RCC lines. The cell lines are shown on the top. Total RNA from the cell lines was reverse transcribed (RT þ ) and amplified to plateau levels by PCR. HOXB13 expression was totally suppressed in the highly methylated cell lines UMRC-6, KC-12, VHL-renal, and SKRC-7. (c) Effect of treating hypermethylated RCC lines with a methyltransferase inhibitor on HOXB13 expression. Three lines that failed to express HOXB13 (UMRC-6, KC-12, and VHL-renal) were incubated with (1 mM) or without (0 mM) 5-aza-dC for 72 h and/or 300 nM of TSA for 24 h, after which total RNA was extracted and subjected to RT-PCR.
HOXB13 methylation in renal cell carcinoma H Okuda et al we expressed FLAG-tagged HOXB13 in the human RCC line KC-12, in which HOXB13 was completely methylated and silenced, by transfecting it with the pLP-IRES-FLAG-HOXB13 expression vector and then subjecting it to a colony formation assay (Figure 5a and b). As a control, the cells were also transfected with pLP-IRESneo empty vector. The re-expression of HOXB13 significantly reduced the number of colonies that formed, indicating HOXB13 can repress cell growth.
Re-expression of HOXB13 induces apoptosis in RCC cells
Since the exogenous expression of HOXB13 repressed the proliferation of hypermethylated RCCs, we investigated whether it also induces apoptosis in RCC cells. Thus, we transfected UMRC-6 RCC cells, which lack HOXB13 expression due to hypermethylation, with the FLAG-HOXB13 or EGFP expression vector, and observed the cells for morphological changes such as nuclear disintegration. After 48 h cultivation, the transfected cells were subjected to the TUNEL assay and also stained with DAPI, a DNA-binding fluorescent dye.
The expression of HOXB13 increased the number of apoptotic cells with nuclear condensation and TUNEL-positive staining, and resulted in cell death (Figure 6a ). In contrast, the control EGFP-expressing cells did not show any increase in apoptotic cell death. Transfected cells were also stained with anti-cleaved caspase-3 antibody (Figure 6b ). The HOXB13-expressing cells showed the induction of caspase-3 activation accompanied with nuclear condensation. These results indicate that HOXB13 can induce apoptosis via the caspase-dependent pathway in RCC cells.
Comparison of HOXB13 methylation status with that of other genes in RCC
To compare the frequency with which HOXB13 is methylated in RCC to that of other tumor-associated genes, we next assessed the methylation status of 13 known CpG islands in 40 primary RCC cases and 16 of the RCC lines by using the COBRA method. These CpG islands contain 11 genes (p14ARF, p15INK4B, p16INK4A, CHFR, CACNA1G, TMS1, BNIP3, COX-2, hMLH1, DAPK, and DCC) and two CpG islands (MINT1 and MINT2) that are known to be frequently hypermethylated in various tumors. A summary of the methylation profiles of these genes is shown in Table 2 . Of these CpG islands, six (CHFR, CACNA1G, COX-2, TMS1, DAPK, and MINT1) were methylated in primary RCC with low methylation frequencies ranging from 3 to 18%. The remaining genes (p14ARF, p15INK4B, p16INK4A, BNIP3, hMLH1, DCC, and MINT2) were not methylated. Thus, unlike HOXB13, which is frequently methylated in primary RCC (30%), these genes are relatively infrequently methylated in primary RCC. HOXB13 methylation in renal cell carcinoma H Okuda et al
Correlation between HOXB13 methylation and clinical and pathological factors
The clinical and pathological characteristics of the 56 primary RCC cases tested are summarized in Table 3 . The associations between HOXB13 methylation and sex, age, tumor grade, clinical stage, tumor size, microvessel invasion, metastasis, and VHL inactivation were analysed by w 2 -test. HOXB13 methylation correlated significantly with grade, stage, tumor size, and microvessel invasion (Table 3 ; Po0.05). Next, the associations between HOXB13 methylation and clinical and pathological parameters were analysed by multivariate analysis using a logistic regression model. HOXB13 methylation correlated significantly with tumor grade and microvessel invasion (Table 4 ; Po0.05). There was no correlation between HOXB13 methylation and VHL inactivation.
Discussion
Along with genetic alterations, epigenetic changes such as DNA methylation play a key role in silencing tumor suppressor genes in cancer. Although several studies have investigated aberrant DNA methylation in human RCC, they focused on well-known tumor-associated genes in other human cancers, such as RASSF1A (Dreijerink et al., 2001; Morrissey et al., 2001; Yoon et al., 2001; Tokinaga et al., 2004) and Timp-3 (Dulaimi et al., 2004) , and comprehensive methods to screen for methylated CpG islands in human RCC have not been employed.
Here, we applied MCA/RDA, a genome-scanning technique, to isolate the differentially methylated CpG islands in RCC cell lines for the first time. This led to the identification of 27 CpG islands. Analysis of the 
HOXB13 methylation in renal cell carcinoma H Okuda et al methylation status of these CpG islands in primary RCC samples revealed that four were highly methylated in the primary cancers, while such methylation was never observed in the paired noncancerous kidney samples. Of these four CpG islands, three were not associated with a known gene. However, the fourth island was located in the upstream region of the HOXB13 gene. We found that the HOXB13 was frequently methylated in primary RCCs (30%) and in human RCC lines (73%), and that the methylation was a tumor-specific phenomenon. As it was not observed in adjacent normal kidney tissue, this methylation event is not age-related. Expression analysis using RT-PCR revealed the profound loss of HOXB13 expression in those RCC lines that showed complete methylation of the 5 0 CpG islands of the HOXB13 gene. Furthermore, the expression of HOXB13 was restored in these hypermethylated RCC lines by treatment with the methyltransferase inhibitor 5-aza-dC, but not by the HDAC inhibitor, indicating that the inactivation of the gene is controlled in a methylation-dependent manner. In addition, exogenous expression of HOXB13 in the RCC lines lacking endogenous HOXB13 expression suppressed cell proliferation and induced apoptosis. These results suggest that the gene silencing of HOXB13 by aberrant methylation of its 5 0 region may contribute to the tumorigenesis or multi-step progression of renal cancer.
Hox genes are known to encode transcription factors that play crucial roles in patterning along the anteriorposterior axis in the developing embryo. A previous report showed that loss-of-function mutations in the murine Hoxb13 gene cause overgrowth of the secondary neural tube, the caudal spinal ganglia, and the caudal vertebrae, which are derived from the tail bud . Furthermore, Hoxb13 is also expressed in the prostate gland of the adult mouse (Sreenath et al., 1999) . In addition, mice lacking Hoxb13 showed hypoplasia of the ventral prostate duct tips and did not produce secretory proteins, suggesting that Hoxb13 is required for the normal differentiation of the ventral prostate . A recent report also showed that ectopic expression of HOXB13 in a prostate cancer cell line induced G1 cell cycle arrest through negative regulation of T-cell factor-4, but did not lead to apoptotic change (Jung et al., 2004a) . However, these reports did not mention the expression of HOXB13 in the kidney or renal tubular cells. A noteworthy fact is that the HOXB13 gene is located on chromosome 17q, whose loss of heterozygosity in RCC has been reported previously (Morita et al., 1991; Mertens et al, 1997) . In our study, we showed that the exogenous expression of HOXB13 in RCC cells that lacked endogenous HOXB13 expression resulted in their nuclear condensation and subsequent cell death. Among the cells that expressed HOXB13 exogenously, an increased number of TUNEL-positive cells were also observed, suggesting that the cell death was caused by apoptosis. Since a former report showed that Hoxb13 activates apoptosis in the secondary neural tube and the caudal extremity of the developing embryo , it is likely that the transcriptional target genes of HOXB13 may also participate in the cell death involved in the normal formation and maintenance of the urogenital system. Significantly, reexpression of HOXB13 suppressed the colony-forming ability of RCC cells. These results indicate that Relationship between DNA methylation of several HOX genes (HOXB1-9) and their expression in lung cancer was formerly reported (Flagiello et al., 1996) , but the study mostly assessed the methylation of 3 0 end of the genes. However, in cancer cell, abnormal methylation of 5 0 promoter region is mainly correlated with transcriptional gene silencing. Therefore, further methylation analysis of the 5 0 region is required to elucidate the mechanisms for epigenetic inactivation of HOX genes. Our results showed that the dense methylation of the 5 0 region of HOXB13 gene causes its transcriptional silencing for the first time. In this study, although bisulfite-sequencing analysis indicated that few CpG sites were sparsely methylated in normal tissues, immunohistochemical analysis showed the expression of HOXB13 in normal tissues and suggested that the methylation of the fifth and ninth CpG sites indicated in Figure 1c would not affect the promoter function.
We also sought to analyse the methylation in RCC of other well-known tumor-associated genes that are frequently methylated in other cancers (Herman et al., 1996 (Herman et al., , 1998 Katzenellenbogen et al., 1999; Toyota et al., 1999a Toyota et al., , c, 2003 Esteller et al., 2000; Baylin et al., 2001; Sato et al., 2001; Ogi et al., 2002; Kikuchi et al., 2002; Herman and Baylin, 2003; Satoh et al., 2003; Okami et al., 2004; Terasawa et al., 2004) to clarify whether the frequent inactivation of HOXB13 in primary RCC is significant. We could not detect the methylation of p14ARF, p15INK4B, p16INK4A, BNIP3, hMLH1, DCC, and MINT2, and only low methylation frequencies (o18%) in CHFR, CACNA1G, TMS1, DAPK, COX-2, and MINT1 were detected, suggesting that these genes are not the main targets for methylation in RCC. These observations indicate the gene set in RCC that is aberrantly methylated and involved in renal carcinogenesis may differ from those that are methylated in other cancers. They also suggest that the HOXB13 gene is a characteristic gene methylated in RCC.
Statistical analysis of the clinicopathological features of the primary RCC patients we tested showed that there were positive correlations between HOXB13 methylation and tumor grade, clinical stage, tumor size, and microvessel invasion. In contrast, we could not find any relationship between HOXB13 methylation and VHL tumor suppressor gene inactivation. Thus, the epigenetic inactivation of HOXB13 is independent of the VHL status. This may help us to elucidate the tumorigenic mechanisms of RCCs that lack VHL inactivation, which constitute approximately 40% of the sporadic clear cell RCC cases (Foster et al., 1994; Gnarra et al., 1994; Herman et al., 1994; Shuin et al., 1994 Shuin et al., , 1999 . Notably, multivariate analysis of the clinicopathological parameters using a logistic regression model showed that HOXB13 methylation correlated significantly with tumor grade and microvessel invasion. This suggests that the inactivation of HOXB13 may increase the malignant potential of renal cancer.
In conclusion, the results of this study show that HOXB13 is frequently transcriptionally silenced by aberrant DNA methylation in RCC. We also found that HOXB13 represses cell proliferation via an apoptotic pathway. Since the function of HOXB13 in human renal tubular cells (from which human RCC originates) is not known, it is important to study the role of HOXB13 in the development of the kidney, as this may help us to understand the mechanisms that lead to renal carcinogenesis. In addition, as HOXB13 is methylated specifically in RCC with a high frequency, but not methylated in normal kidney tissues, the methylation of HOXB13 in clinical samples may serve as a valuable novel diagnostic biomarker for the early detection of RCC.
Materials and methods

Cell lines and samples
The following 17 human RCC lines were used: KMRC-1, KMRC-2, 786-O, UMRC-6 (kindly provided by Dr B Zbar of the National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD, USA), KC-12, ACHN, A498, OUR-10, OUR-20, VHL-renal, YCR, Caki-1, Caki-2, SKRC-1, SKRC-7, TUHR4TKB, and TUHR14TKB. KMRC-1 and KMRC-2 were established in our institution. SKRC-1 and SKRC-7 were kind gifts from Dr H Uemura (Kinki University, Osaka, Japan). TUHR4TKB and TUHR14TKB were obtained from the RIKEN Cell Bank. In all, 56 primary RCCs and matched adjacent normal tissues were obtained from Japanese RCC patients (denoted as case 1-68) by surgical resection with written informed consent of the patients. The pathology of all the primary renal tumors was assessed according to general Japanese rules (Kanehara Company, 1999) . Genomic DNA was extracted from the cell lines and tissue specimens by standard phenol/chloroform extraction methods.
Methylated CpG island amplification/representational difference analysis MCA/RDA was performed as described by Toyota et al. (Toyota et al., 1999b; Ueki et al., 2001 ) with a few modifications. Briefly, 5 mg of DNA was digested with 100 U of SmaI (New England Biolabs, Beverly, MA, USA) and then with 20 U of XmaI (New England Biolabs). An RMCA PCR adaptor was prepared by incubating RMCA12 (5 0 -CCG GGCAGAAAG-3 0 ) and RMCA24 (5 0 -CCACCGCCATCCG AGCCTTTCTGC-3 0 ) at 651C for 2 min, followed by cooling to room temperature. The restriction fragments (0.5 mg) were ligated to 0.5 nmol of this RMCA adaptor by using T4 DNA ligase (TAKARA, Tokyo, Japan) and 3 ml of each ligation mix was subjected to PCR amplification in 16.6 mM Tris-HCl (pH 8.0), 4 mM MgCl 2 , 166 mM (NH 4 ) 2 SO 4 , 0.1 mg/ml BSA, 5% v/ v DMSO, 300 mM each deoxynucleotide triphosphate, 200 pmol of RMCA24 primer, and 15 U of Taq polymerase (TAKARA) in a final reaction volume of 200 ml. The reaction mixture was incubated at 721C for 5 min and then subjected to 25 cycles of 1 min at 951C and 3 min at 771C, followed by a final extension at 721C for 10 min. For the RDA, the MCA amplicon from either the RCC cell line KMRC-1 or KMRC-2 was used as the tester, and the MCA amplicon from a mixture of DNA derived from the normal kidney tissue of four individual patients (two were male and two were female) was used as the driver. The JMCA PCR adaptor was used for the first round of RDA and the NMCA PCR adaptor was used for the second round. Primers used for the JMCA and NMCA were as follows:
HOXB13 methylation in renal cell carcinoma H Okuda et al NMCA24 (5 0 -GTTAGCGGACACAGGGCGGGTCAC-3 0 ), and NMCA12 (5 0 -CCGGGTGACCCG-3 0 ). For the first and second rounds of competitive hybridization, 500 and 100 ng of tester amplicon ligated to each adaptor were used, respectively. After two rounds of competitive hybridization and selective PCR amplification, the RDA products were cloned into the pBluescript II plasmid vector (Stratagene, La Jolla, CA, USA). The DNA sequence of the isolated clones was determined by using an ABI 3100 automated DNA sequencer and BigDye Terminator cycle sequencing kit ver.3 (Applied Biosystems, Foster City, CA, USA) with the MT-T3 primer (SIGMA, St Louis, MO, USA). Sequences with homology to the sequences thus derived were obtained by using the BLAST program (National Center for Biotechnology Information, http:// www.ncbi.nlm.nih.gov/BLAST/). The regions of the CpG islands were determined by using CpG island Searcher (http://cpgislands.usc.edu/).
COBRA
Genomic DNA from RCC lines, primary tumors, and adjacent normal tissue was treated with sodium bisulfite as described previously (Clark et al., 1994) . COBRA was carried out as described previously (Xiong and Laird, 1997) . Briefly, 2 ml aliquots of bisulfite-treated DNA solution were amplified in a 50 ml reaction mixture containing 67 mM Tris-HCl (pH 8.8), 16.6 mM (NH 4 ) 2 SO 4 , 6.7 mM MgCl 2 , 10 mM b-mercaptoethanol, 2.5 mM of each dNTP mixture, 0.5 mM of each primer, and 1 U of Ex Taq Hot Start Version polymerase (TAKARA). The amplified products (15-20 ml) were then digested with restriction enzymes that recognize CpG sites retained by bisulfite treatment because of methylation. The primer pairs used for HOXB13 were: MIRC9-2F, 5 0 -GGGTAAAGTATTTTYGTA GTTTT-3 0 , and MIRC9-2R, 5 0 -CCTTAACTCCATCCA AAATAAC-3 0 , or MIRC9-3F, 5 0 -AGAGAGAGAGAGAGA ATAAGT-3 0 , and MIRC9-3R, 5 0 -AAATCTAAAAAACA CCCAACTC-3 0 . The PCR conditions were 3 min at 941C followed by 35 cycles of 40 s of 941C, 30 s of 601C for MIRC9-2 (or 581C for MIRC9-3), and 30 s of 721C. The restriction enzyme used for HOXB13 was BstUI (New England Biolabs). The primer sequences, PCR parameters, and the restriction enzymes used for the COBRA of other genes (p14ARF, p15INK4B, p16INK4A, CHFR, CACNA1G, TMS1, BNIP3, COX-2, hMLH1, DAPK, DCC, MINT1, and MINT2) have been described previously (Kikuchi et al., 2002; Ogi et al., 2002; Satoh et al., 2003; Terasawa et al., 2004) . The resultant DNA fragments were electrophoresed in 2.5% agarose gels and stained with ethidium bromide.
Bisulfite-sequencing analysis
To sequence the bisulfite-PCR products, the fragments were amplified with the MIRC9-3F and MIRC9-2R primers and then cloned into pGEM-T Easy vector by using pGEM-T Easy Vector Systems (Promega, Madison, WI, USA). At least 10 clones for each primary RCC sample or cell line were sequenced. The DNA sequence was determined by using BigDye Terminator cycle sequencing kit ver.1.1 (Applied Biosystems) and an ABI 3100 automated DNA sequencer.
RT-PCR
In all, 15 RCC lines (786-O, UMRC-6, KC-12, ACHN, A498, OUR-10, OUR-20, VHL-renal, YCR, Caki-1, Caki-2, SKRC-1, SKRC-7, TUHR4TKB, and TUHR14TKB) were used to analyse HOXB13 expression by RT-PCR. To investigate the effect of demethylation on HOXB13 expression, three cell lines (UMRC-6, KC-12, and VHL-renal) were treated with 1 mM of the demethylating agent 5-aza-dC for 3 days. The cells were also treated with 300 nM of the HDAC inhibitor TSA for 1 day to estimate the effect of histone acetylation. Total RNA from each cell line was prepared by using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), and then reverse-transcribed by using Oligo(dT)15 primer (Promega) and the Omniscript RT Kit (Qiagen) according to the manufacturer's instructions. Total RNA from normal human tissues was purchased from Clontech Laboratories (Palo Alto, CA, USA). The expression of HOXB13 was determined by RT-PCR using the primers, H13F, 5 0 -TTGCCTGTGGACAGTTACC-3 0 , and H13R, 5 0 -AACTTGTTAGCCGCATACTC-3 0 . As a control for RNA integrity, the gene encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified with the following primers: GAPDHUP, 5 0 -CGGATTTGGTCGTATTGG and GAPDHLW, 5 0 -TCCTGGAAGATGGTGATG-3 0 .
Construction of a FLAG-tagged HOXB13 expression vector Human HOXB13 cDNA on the pDNR-Dual vector was purchased from Open Biosystems (Huntsville, AL, USA), Cterminally linked to the FLAG-tag, and then subcloned into the pLP-IRESneo expression vector (Clontech). The EGFP gene in pDNR-EGFP (Clontech) was also subcloned into the pLP-IRESneo vector.
Immunohistochemical analysis
The polyclonal antibody against HOXB13 was prepared by immunizing rabbits with a chemically synthesized peptide (RVKEKKVLAKVKNS) corresponding to a 14-amino-acid sequence in human HOXB13. Based on the methylation status of each primary RCC case as analysed by COBRA, we selected 11 RCCs, three of which showed HOXB13 methylation, while the remaining eight lacked HOXB13 methylation. Sections from archival formalin-fixed paraffin-embedded tissues (5 mmthick) of the 11 RCCs were placed on slides for immunohistochemistry (IHC) using the Ventana automated IHC system (DiscoveryTM, Ventana Medical systems, Inc., Tucson, AZ, USA). Deparaffinized tissue sections were heated to 1081C for 16 min for antigen retrieval and then incubated with the diluted anti-HOXB13 antibody (3.4 mg/ml). The automated protocol is based on an indirect biotin-avidin system and uses a biotinylated universal secondary antibody and diaminobenzidine substrate and hematoxylin counterstain.
Colony formation assay
In total, 8 mg of vector DNA was transfected by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The expression vectors used were pLP-IRES-FLAG-HOXB13 and pLP-IRESneo. Cells (5 Â 10 4 ) were plated in 100 mm dishes for 24 h after transfection, cultured for 14 days in medium containing 0.5 mg/ml G418 and then stained with Giemsa. Colony counts were performed with triplicate cultures.
Immunofluorescence microscopy Cells grown on a coverslip in 60 mm dishes were transfected with 5 mg of pLP-IRES-FLAG-HOXB13 or pLP-IRES-EGFP vector DNA by using TransFast Transfection Reagent (Promega). After 48 h cultivation, the cells on the coverslips were washed twice with PBS and fixed with 3% paraformaldehyde in PBS for 20 min at room temperature. The cells were then permeabilized with 0.1% Triton X-100 in PBS for 3 min and blocked in PBS containing 10% goat serum for 30 min at room temperature. The samples were incubated at 371C for 60 min with the primary anti-FLAG M2 antibody (SIGMA) in buffer containing 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween 20, and 0.1% BSA. The secondary antibody used was Alexa Fluor 488 goat anti-mouse IgG (Molecular Probes, Eugene, OR, USA). For the TUNEL assay, the ApopTag Red In situ Apoptosis Detection Kit (Chemicon, Temecula, CA, USA) was used according to the manufacturer's instructions. To detect the activation of caspase-3, the samples were incubated at 371C for 60 min with anti-cleaved caspase-3 antibody (Cell Signaling Technology, Beverly, MA, USA) in a buffer containing 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween 20, and 0.1% BSA. The secondary antibody used was Alexa Fluor 568 goat anti-rabbit IgG (Molecular Probes). Coverslips were mounted with VECTASHIELD Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA, USA) and examined under a fluorescence microscope.
Statistical analysis
The statistical relationships between HOXB13 methylation and sex, age, tumor grade, clinical stage, tumor size, microvessel invasion, metastasis, and VHL inactivation were analysed by w 2 -test and multivariate analysis using a logistic regression model. A value of Po0.05 was considered to be significant. All P-values are two-sided.
